nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.11.2010 | Editorial Commentary

A new PET probe, ¹⁸F-tetrafluoroborate, for the sodium/iodide symporter: possible impacts on nuclear medicine

verfasst von: Hyewon Youn, Jae Min Jeong, June-Key Chung

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 11/2010

Einloggen, um Zugang zu erhalten

Excerpt

As early as 1915, it was found that iodide is required in the thyroid gland for the production of thyroid hormones. Since then, radioiodines have been used as tracers in thyroid function tests and as agents for the treatment of hyperthyroidism and benign thyroid diseases. Furthermore, knowledge of the importance of the role played by iodine transport in thyroid cancer cells provides the rationale for the use of radioiodines to diagnose and treat thyroid cancer (1, 2). In fact, the clinical utilization of radioiodines led to the birth of nuclear medicine. …

Fernandes JK, Day TA, Richardson MS, Sharma AK. Overview of the management of differentiated thyroid cancer. Curr Treat Options Oncol 2005;6:47–57.CrossRefPubMed

Chung J-K, Youn HW, Kang JH, Lee HY, Kang KW. Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma. Nucl Med Mol Imaging 2010;44:4–14.CrossRef

Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996;379:458–60.CrossRefPubMed

Caillou B, Troalen F, Baudin E, Talbot M, Filetti S, Schlumberg M, et al. Na+/I- symporter distribution in human thyroid tissues: an immunohistochemical study. J Clin Endocrinol Metab 1998;83:4102–6.CrossRefPubMed

Chung J-K. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med 2002;43:1188–200.PubMed

Van Sande J, Massart C, Beauwens R, Schoutens A, Costagliola S, Dumont JE, et al. Anion selectivity by the sodium iodide symporter. Endocrinology 2003;144:247–52.CrossRefPubMed

Anbar M, Guttmann S, Lewitus Z. Effect of monofluorosulphonate, difluorophosphate and fluoroborate ions on the iodine uptake of the thyroid gland. Nature 1959;183:1517–8.CrossRefPubMed

Anbar M, Guttmann S, Lewitus Z. The accumulation of fluoroborate ions in thyroid glands of rats. Endocrinology 1960;66:888–90.CrossRefPubMed

Lambrecht RM, Sajjad M, Qureshi MA, Al-Yanbawi SJ. Production of ¹²⁴I. J Radioanal Nucl Chem Lett 1988;127:143–50.CrossRef

10.

Jauregui-Osoro M, Sunassee K, Weeks AJ, Berry DJ, Paul RL, Cleij M, et al. Synthesis and biological evaluation of [¹⁸F]tetrafluoroborate: a PET imaging agent for thyroid disease and reporter gene imaging of the sodium/iodide symporter. Eur J Nucl Med Mol Imaging 2010;doi:10.1007/s00259-010-1523-0

11.

Eschmann SM, Reischl G, Bilger K, Kupferschläger J, Thelen MH, Dohmen BM, et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging 2002;29:760–7.CrossRefPubMed

12.

Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, et al. Patient-specific dosimetry for ¹³¹I thyroid cancer therapy using ¹²⁴I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004;45:1366–72.PubMed

13.

Freudenberg LS, Jentzen W, Görges R, Petrich T, Marlowe RJ, Knust J, et al. ¹²⁴I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin 2007;46:121–8.PubMed

14.

Filetti S, Bidart J-M, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 1999;141:443–57.CrossRefPubMed

15.

Min J-J, Chung J-K, Lee YJ, Jeong JM, Lee DS, Jang JJ, et al. Relationship between expression of the sodium/iodide symporter and ¹³¹I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med 2001;28:639–45.CrossRefPubMed

16.

Chung J-K, Kang JH. Translational research using the sodium/iodide symporter in imaging and therapy. Eur J Nucl Med Mol Imaging 2004;31:799–802.CrossRefPubMed

Titel: A new PET probe, 18F-tetrafluoroborate, for the sodium/iodide symporter: possible impacts on nuclear medicine
verfasst von: Hyewon Youn
Jae Min Jeong
June-Key Chung
Publikationsdatum: 01.11.2010
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 11/2010
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-010-1601-3

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2010

PET with 18F-labelled choline-based tracers for tumour imaging: a review of the literature

FDG PET/CT and diffusion-weighted imaging for breast cancer: prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion

Assessment of inflammation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia

Reduced dimethylaminoethanol in [18F]fluoromethylcholine: an important step towards enhanced tumour visualization

Pre- and postsynaptic dopamine SPECT in the early phase of idiopathic parkinsonism: a population-based study

Nuclear medicine: what kind of quality would we want if we were the patient?